Agenus/$AGEN
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Agenus
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Ticker
$AGEN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
316
Website
Agenus Metrics
BasicAdvanced
$151M
-
-$8.48
1.48
-
Price and volume
Market cap
$151M
Beta
1.48
52-week high
$7.34
52-week low
$1.38
Average daily volume
1.3M
Financial strength
Current ratio
0.111
Quick ratio
0.09
Long term debt to equity
-26.932
Total debt to equity
-28.549
Interest coverage (TTM)
-1.01%
Profitability
EBITDA (TTM)
-91.686
Gross margin (TTM)
-34.28%
Net profit margin (TTM)
-191.50%
Operating margin (TTM)
-105.36%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-28.70%
Return on equity (TTM)
76.14%
Valuation
Price to revenue (TTM)
1.248
Price to book
-0.43
Price to tangible book (TTM)
-0.4
Price to free cash flow (TTM)
-0.849
Free cash flow yield (TTM)
-117.79%
Free cash flow per share (TTM)
-6.502
Growth
Revenue change (TTM)
-38.34%
Earnings per share change (TTM)
-32.67%
3-year revenue growth (CAGR)
-31.52%
10-year revenue growth (CAGR)
25.57%
3-year earnings per share growth (CAGR)
76.46%
10-year earnings per share growth (CAGR)
-7.82%
What the Analysts think about Agenus
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Agenus Financial Performance
Revenues and expenses
Agenus Earnings Performance
Company profitability
Agenus News
AllArticlesVideos
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
Business Wire·1 day ago
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
Business Wire·1 week ago
Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agenus stock?
Agenus (AGEN) has a market cap of $151M as of August 01, 2025.
What is the P/E ratio for Agenus stock?
The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of August 01, 2025.
Does Agenus stock pay dividends?
No, Agenus (AGEN) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Agenus dividend payment date?
Agenus (AGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Agenus?
Agenus (AGEN) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.